Gilead & Merck announce phase 2 data showing a treatment switch to an investigational oral once-weekly combination regimen of islatravir & lenacapavir maintained viral suppression in adults at week 48

Gilead Sciences, Inc. and Merck, known as MSD outside of the United States and Canada, announced new results from a phase 2 clinical study evaluating the investigational combination of islatravir, [...]